Two peptides, two different jobs — and the reason they’re almost always studied as a pair.
CJC-1295 and Ipamorelin show up together so often that it’s easy to assume they’re the same kind of thing. They aren’t — and understanding the difference is the whole point of the pairing.
Two different signals
CJC-1295 is a GHRH analogue — it mimics growth hormone-releasing hormone, the signal that tells the pituitary to release growth hormone. Ipamorelin is a GHRP, or growth hormone-releasing peptide, which works through a completely separate receptor (the ghrelin/GHS receptor). One presses the accelerator; the other releases a different brake.
Because they act on two distinct pathways, researchers study them together to see how the pathways interact — something neither peptide can show alone.
What makes Ipamorelin notable
Ipamorelin earned its reputation for selectivity. Earlier GHRPs tended to also nudge hormones like cortisol and prolactin; Ipamorelin is studied precisely because it’s cleaner, which makes it a useful research tool when you want to isolate the growth-hormone pathway.
A note on CJC-1295 “DAC”
You’ll see CJC-1295 with and without DAC (a drug-affinity complex that dramatically extends its half-life). Our blend uses the no-DAC form paired with Ipamorelin — the most-referenced version of this combination in the research literature. For the longer-acting GHRH story on its own, Tesamorelin is the clinically-validated reference point.
Handling in the lab
Supplied lyophilised in a single vial, reconstituted with bacteriostatic water and refrigerated once mixed. ≥99% HPLC purity with Janoshik verification on the product page.
In the catalogue
CJC-1295 / Ipamorelin
Stocked in our UK warehouse at ≥99% HPLC purity, Janoshik independently tested.
View CJC-1295 / Ipamorelin in the shop →← Back to the Library
